– USA, NC – Focal Medical, Inc., a biopharmaceutical company developing novel therapeutic products, today announced the appointment of Michael Aldridge as CEO, succeeding Tony Voiers, who is stepping into the COO role.
Michael joins Focal Medical with more than 25 years of experience in the biopharma industry.
“I am excited to announce the new company name, Focal Medical, as well as our new CEO, Michael Aldridge. Michael brings a great breadth of experience to the position, having led successful life science startups and growth stage companies including Peplin, Questcor Pharmaceuticals, Codexis, and most recently Hexima. I’d also like to thank Tony Voiers for his service as CEO these past six years and for his future service as COO,” said Founder and Board Chairman, Joseph DeSimone.
The Board of Directors includes:
- Dr. Joseph DeSimone (Ph.D.) Founder, the Sanjiv Sam Gambhir Professor of Translational Medicine and Chemical Engineering at Stanford University,
- Dr. Jen Jen Yeh, (M.D.) Founder, Professor, Departments of Surgery and Pharmacology, Vice-Chair of Research Department of Surgery and Director of the Pancreatic Cancer Center of Excellence at the Lineberger Comprehensive Cancer Center, University of North Carolina School of Medicine
- Paula Hammond, Institute Professor and Department Head Department of Chemical Engineering, Massachusetts Institute of Technology,
- Michael Aldridge, CEO
- Tony Voiers, CTO
“I’m thrilled and humbled to be joining the Focal Medical team as CEO,” said Michael Aldridge. “The team has been outstanding, demonstrating the potential of Focal Medical’s local drug delivery platform and we are well positioned to take a giant leap forward into new product opportunities. I’m excited to lead the Company into a new era of innovative therapeutic products based on Focal Medical’s energy-based delivery platform, particularly in oncology and gene therapy.”
About Focal Medical
Focal Medical, Inc. is a privately held, biopharmaceutical company developing novel therapeutic products based on its innovative and patent-protected local drug delivery technology platform. Focal Medical’s patented iontophoresis delivery system enables the internal, site-specific delivery of therapeutics actively, directly, and selectively to the diseased target tissue or organ. The technology thus addresses certain significant challenges and limitations of traditional systemic drug delivery approaches including toxicity and first-pass metabolism. Focal Medical’s lead product uses its patented iontophoresis system for the local delivery of gemcitabine actively and directly to the tumor to treat pancreatic cancer. Focal Medical is expanding its product focus into therapies for other solid tumors and gene therapy products, all utilizing its innovative energy-based drug delivery system.
Focal Medical is the new name of Advanced Chemotherapy Technologies. Focal Medical’s corporate rebranding is a function of a strategic shift towards broader product applications of its targeted drug delivery technology. Focal Medical has raised over $20 million in equity and grant funding to date. Institutional investors include Khosla Ventures, Spectrum Financial and Piedmont Capital Partners.
For more information: https://focalmedical.co/
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.
